scispace - formally typeset
G

Gil Bar-Sela

Researcher at Emek Medical Center

Publications -  164
Citations -  4870

Gil Bar-Sela is an academic researcher from Emek Medical Center. The author has contributed to research in topics: Cancer & Cannabis. The author has an hindex of 31, co-authored 164 publications receiving 3744 citations. Previous affiliations of Gil Bar-Sela include University of North Carolina at Chapel Hill & Rambam Health Care Campus.

Papers
More filters
Journal ArticleDOI

Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications

TL;DR: Curcumin's potent anti-proliferative activity interacting with several intracellular signal transduction pathways may potentiate the anti-tumor effect of gemcitabine.
Journal ArticleDOI

Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer

TL;DR: Low compliance for curcumin at a dose of 8,000 mg/day, when taken together with systemic gemcitabine, may prevent the use of high doses of oralCurcumin needed to achieve systemic effect in cancer patients.
Journal ArticleDOI

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander M.M. Eggermont, +131 more
- 01 May 2021 - 
TL;DR: In this paper, the authors compared pembrolizumab versus placebo in patients with resected high-risk stage III melanoma, and showed that penglizumaab adjuvant therapy provided a significant and clinically meaningful improvement in distant metastasis-free survival at a 3·5-year median followup.
Journal ArticleDOI

Art therapy improved depression and influenced fatigue levels in cancer patients on chemotherapy

TL;DR: This study was to determine whether improvement in depression, anxiety or fatigue during chemotherapy following anthroposophy art therapy intervention is substantial enough to warrant a controlled trial.